Reuters logo
BRIEF-Biofrontera reports detailed phase III results for Ameluz
March 13, 2017 / 8:07 AM / 8 months ago

BRIEF-Biofrontera reports detailed phase III results for Ameluz

March 13 (Reuters) - Biofrontera AG:

* Reports detailed phase III results for Ameluz in combination with daylight-PDT

* Data show daylight photodynamic therapy (PDT) with Ameluz provided excellent results for primary and all secondary study endpoints

* EMA filing for EU approval of daylight PDT for actinic keratosis (AK) expected in Q2 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below